Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses...